KR102314654B1 - Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component - Google Patents
Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component Download PDFInfo
- Publication number
- KR102314654B1 KR102314654B1 KR1020190164117A KR20190164117A KR102314654B1 KR 102314654 B1 KR102314654 B1 KR 102314654B1 KR 1020190164117 A KR1020190164117 A KR 1020190164117A KR 20190164117 A KR20190164117 A KR 20190164117A KR 102314654 B1 KR102314654 B1 KR 102314654B1
- Authority
- KR
- South Korea
- Prior art keywords
- centella asiatica
- fermented
- asiatica extract
- extract
- fermented centella
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 22
- 230000037303 wrinkles Effects 0.000 title claims abstract description 20
- 244000146462 Centella asiatica Species 0.000 title claims description 14
- 235000004032 Centella asiatica Nutrition 0.000 title claims description 14
- 206010061218 Inflammation Diseases 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 title description 6
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 94
- 239000002537 cosmetic Substances 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 230000036541 health Effects 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 14
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 29
- 102000003820 Lipoxygenases Human genes 0.000 description 21
- 108090000128 Lipoxygenases Proteins 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 17
- 230000004151 fermentation Effects 0.000 description 17
- 230000002849 elastaseinhibitory effect Effects 0.000 description 13
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 240000001929 Lactobacillus brevis Species 0.000 description 10
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- -1 fatty acid esters Chemical class 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 244000063299 Bacillus subtilis Species 0.000 description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 7
- 102000016387 Pancreatic elastase Human genes 0.000 description 7
- 108010067372 Pancreatic elastase Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 4
- MUCRYNWJQNHDJH-UHFFFAOYSA-N Ursonic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C MUCRYNWJQNHDJH-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000014171 carbonated beverage Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008204 material by function Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229940095050 propylene Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 함유하는 피부주름 개선 또는 항염증용 조성물에 관한 것으로, 본 발명의 발효 병풀 추출물은 항산화, 피부주름 개선 및 항염 효과가 우수하므로, 피부주름 개선을 위한 화장료, 건강기능식품 및 피부 외용제, 염증 개선을 위한 식품 및 치료제로 유용하게 사용할 수 있다. The present invention relates to a skin wrinkle improvement or anti-inflammatory composition comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient. It can be usefully used as a cosmetic for improvement, health functional food and external preparation for skin, and as a food and therapeutic agent for improving inflammation.
Description
본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 함유하는 피부주름 개선 또는 항염증용 조성물에 관한 것이다.The present invention relates to an anti-wrinkle or anti-inflammatory composition comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
최근 국내외 소비자들의 화장품에 대한 지식과 인식 수준의 상승으로 새로운 기대를 충족시킬 수 있는 고부가가치 뷰티 제품의 개발이 필요한 실정이다. 특히 한방 및 발효 화장품은 이미 세계적인 트렌드가 된 웰빙, 자연주의를 지향하며 자연 성분을 선호하는 소비자 욕구를 만족시키는 동시에 동양적 정서가 함께 작용하면서 화장품 기업들 대부분이 유통별로 하나 또는 그 이상의 브랜드를 가지고 있을 만큼 독자적인 영역을 구축하고 있다. 불과 몇 년 전까지만 해도 화장품 제조 원료는 합성 화합물이 주를 이루었으나, 천연, 기능성 화장품 시장의 확대로 고부가가치 원료 사용이 증가하면서 국내 화장품 원료 시장 또한 커지고 있는 추세이다. With the recent increase in knowledge and awareness of cosmetics of domestic and foreign consumers, it is necessary to develop high value-added beauty products that can meet new expectations. In particular, oriental medicine and fermented cosmetics aim for well-being and naturalism, which has already become a global trend, and satisfy consumer needs who prefer natural ingredients, and at the same time oriental sentiments work together. We are building our own territory. Until just a few years ago, synthetic compounds were the main raw materials for cosmetics manufacturing, but as the use of high-value-added raw materials increases due to the expansion of the natural and functional cosmetics market, the domestic cosmetics raw material market is also growing.
국내 화장품 산업은 아시아를 중심으로 한 해외진출, 기능성 화장품 및 천연 식물성 화장품의 개발 등에 힘입어 무역흑자를 보이고 있다. 그러나 제조시 사용되는 원료 중 78% 정도가 수입원료에 의존하고 있으므로, 수입의존도를 낮추는 것이 필요한 시점이다. 기능성이 강화된 제품의 소비는 증가하고 있으며, 소비자를 포함한 각 연구기관 및 기업에서는 천연 생리활성 효능를 가진 기능성 소재 개발에 대한 관심이 높아지고 있다.The domestic cosmetics industry is showing a trade surplus thanks to overseas expansion, mainly in Asia, and the development of functional cosmetics and natural plant cosmetics. However, since about 78% of raw materials used in manufacturing depend on imported raw materials, it is necessary to lower the dependence on imports. Consumption of products with enhanced functionality is increasing, and research institutes and companies including consumers are increasingly interested in developing functional materials with natural physiologically active effects.
모든 생물체들은 생체 내 생화학 반응 및 환경적 인자에 의해 활성산소종이 생성되며, 생체 내에서 활성산소종의 생성이 증가된 상태는 산화적 스트레스를 일으켜 세포 내 단백질 및 지질성분 등이 기능적으로 손상될 수 있고, 노화, 심장병, 당뇨병, 관절염 등 다양한 질환의 원인이 되기도 한다. 최근에는 산화적 스트레스에 의한 세포 구성 성분의 산화적 손상을 지연시키거나 억제하는 천연 항산화 물질 및 발효를 이용한 기능성 소재의 개발이 활발히 이루어지고 있다.All living things generate reactive oxygen species by in vivo biochemical reactions and environmental factors, and the increased production of reactive oxygen species in vivo causes oxidative stress, which can cause functional damage to intracellular proteins and lipid components. It can also cause various diseases such as aging, heart disease, diabetes, and arthritis. Recently, the development of functional materials using natural antioxidants and fermentation that delay or inhibit oxidative damage to cell components caused by oxidative stress has been actively developed.
병풀(Centella asiatica)은 산형과에 속하는 포복성 다년생 초본으로 아프리카의 마다가스카르(Madagascar) 섬이 원산지이나 그 외 인도양의 해안지역, 북부 오스트레일리아 및 일부 중남미 등의 고온 다습한 곳에서 폭넓게 자생하며, 국내에서는 난대지방에 속하는 제주도 및 남부지방의 도서지역에 자생하고 있다. 병풀은 상처 치료에 탁월하고, 항치매 및 위장병 등에 효과가 있어 질병 치료제의 원료로 다양하게 사용되고 있다. Centella asiatica is a crawling perennial herb belonging to the Umbrella family, which is native to the African island of Madagascar, but grows widely in high-temperature and high-humidity places such as coastal areas of the Indian Ocean, northern Australia, and parts of Central and South America. It is native to Jeju Island belonging to the temperate region and island regions in the southern region. Centella asiatica is excellent for wound healing and is effective in anti-dementia and gastrointestinal diseases, so it is used variously as a raw material for treating diseases.
한편, 한국등록특허 제1971837호에는 '병풀 부정근 추출물을 유효성분으로 함유하는 피부 미백 및 주름개선용 화장료 조성물'이 개시되어 있고, 한국등록특허 제1914233호에는 '병풀 추출물 및 아스타잔틴을 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물'이 개시되어 있으나, 본 발명의 '항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 함유하는 피부주름 개선 또는 항염증용 조성물'에 대해서는 기재된 바가 없다.On the other hand, Korean Patent No. 1971837 discloses 'a cosmetic composition for skin whitening and wrinkle improvement containing Centella asiatica extract as an active ingredient', and Korean Patent No. 1914233 discloses 'Centella Centella asiatica extract and astaxanthin as active ingredients'. Although a composition for preventing or treating atopic dermatitis comprising
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자들은 병풀(Centella asiatica) 분말에 락토바실러스 퍼멘텀(Lactobacillus fermentum)을 접종하여 고상 발효시킨 후 추출하여 발효 병풀 추출물을 제조하였고, 상기 제조된 발효 병풀 추출물이 발효되지 않은 병풀 추출물에 비해 총 페놀 함량이 증가되고 DPPH 라디칼 소거 활성이 우수할 뿐만 아니라, 피부주름 생성 요인인 엘라스타아제에 대한 활성 저해와 염증 유발인자인 리폭시게나아제의 저해 활성이 현저하게 증가되는 것을 확인함으로써, 본 발명을 완성하였다.The present invention has been derived by the above requirements, and the present inventors inoculated Lactobacillus fermentum into Centella asiatica powder, fermented after solid-phase fermentation, and prepared a fermented Centella asiatica extract, Compared to the unfermented Centella asiatica extract, the total phenol content of the fermented Centella asiatica extract is increased and the DPPH radical scavenging activity is excellent, as well as inhibiting the activity of elastase, which is a factor that creates skin wrinkles, and the inhibitory activity of lipoxygenase, which is an inflammation-inducing factor. By confirming that this significantly increased, the present invention was completed.
상기 과제를 해결하기 위해 본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 피부주름 개선용 화장료 조성물을 제공한다.In order to solve the above problems, the present invention provides a cosmetic composition for improving skin wrinkles comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 피부주름 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for improving skin wrinkles comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 피부주름 개선용 피부외용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for external use for skin wrinkle improvement comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving inflammatory diseases comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
본 발명의 발효 병풀 추출물은 천연 유래의 물질로 인체에 안전하고 장기간 사용하여도 부작용이 없으므로, 피부주름 개선을 위한 화장료, 건강기능식품 또는 피부 외용제, 염증 개선을 위한 식품 및 치료제로 유용하게 사용할 수 있다. The fermented Centella asiatica extract of the present invention is a natural-derived material, safe for the human body, and has no side effects even after long-term use, so it can be usefully used as a cosmetic for improving skin wrinkles, a health functional food or external preparation for skin, and a food and therapeutic agent for improving inflammation. have.
도 1은 비발효 병풀 추출물(NF) 및 발효 병풀 추출물(F/3) 내의 총 페놀 함량을 측정한 결과이다.
도 2는 비발효 병풀 추출물(NF) 및 발효 병풀 추출물(F/3)의 DPPH 라디칼 소거 활성(DPPH radical scavenging activity)을 측정한 결과이다. 양성대조군은 BHT(butylated hydroxytoluene, 0.05%)를 처리한 것이다.
도 3은 비발효 병풀 추출물(NF) 및 발효 병풀 추출물(F/3)의 엘라스타아제 저해 활성(elastase inhibition activity)을 측정한 결과이다. 양성대조군은 URS(ursonic acid, 0.05%)를 처리한 것이다.
도 4는 비발효 병풀 추출물(NF) 및 발효 병풀 추출물(F/3)의 리폭시게나아제 저해 활성(lipoxygenase inhibition activity)을 측정한 결과이다. 양성대조군은 IDM(Indomethacine, 0.05%)을 처리한 것이다.
도 5는 발효 균주에 따른 발효 병풀 추출물의 엘라스타아제 저해 활성을 측정한 결과이다. 양성대조군은 URS(ursonic acid, 0.05%)를 처리한 것이고, NF는 비발효 병풀 추출물 처리군이며, L1106은 락토바실러스 퍼멘텀(Lactobacillus fermentum) L1106 KCTC 3112; Lb는 락토바실러스 브레비스(Lactobacillus brevis) KCTC 3498; Bs는 바실러스 서틸리스(Bacillus subtilis) KACC 91157; 및 S40은 바실러스 속(Bacillus sp.) S-40 균주를 각각 접종하여 제조한 발효 병풀 추출물 처리군을 나타낸다.
도 6은 락토바실러스 퍼멘텀(L1106) 균주를 접종한 후 발효 기간에 따른 발효 병풀 추출물의 엘라스타아제 저해 활성을 측정한 결과이다. 양성대조군은 URS(ursonic acid, 0.05%)를 처리한 것이고, NF는 비발효 병풀 추출물 처리군; F/1은 1일간; F/2는 2일간; F/3은 3일간; F/4는 4일간; 및 F/5는 5일간 각각 발효시켜 제조한 발효 병풀 추출물 처리군을 나타낸다.
도 7은 발효 균주에 따른 발효 병풀 추출물의 리폭시게나아제 저해 활성을 측정한 결과이다. 양성대조군은 IDM(Indomethacine, 0.05%)을 처리한 것이고, NF는 비발효 병풀 추출물 처리군이며, L1106은 락토바실러스 퍼멘텀(Lactobacillus fermentum) L1106 KCTC 3112; Lb는 락토바실러스 브레비스(Lactobacillus brevis) KCTC 3498; Bs는 바실러스 서틸리스(Bacillus subtilis) KACC 91157; 및 S40은 바실러스 속(Bacillus sp.) S-40 균주를 각각 접종하여 제조한 발효 병풀 추출물 처리군을 나타낸다.
도 8은 락토바실러스 퍼멘텀(L1106) 균주를 접종한 후 발효 기간에 따른 발효 병풀 추출물의 리폭시게나아제 저해 활성을 측정한 결과이다. 양성대조군은 IDM(Indomethacine, 0.05%)을 처리한 것이고, NF는 비발효 병풀 추출물 처리군; F/1은 1일간; F/2는 2일간; F/3은 3일간; F/4는은 4일간; 및 F/5는 5일간 각각 발효시켜 제조한 발효 병풀 추출물 처리군을 나타낸다.1 is a result of measuring the total phenol content in non-fermented Centella asiatica extract (NF) and fermented Centella asiatica extract (F/3).
2 is a result of measuring the DPPH radical scavenging activity of non-fermented Centella asiatica extract (NF) and fermented Centella asiatica extract (F/3). The positive control group was treated with BHT (butylated hydroxytoluene, 0.05%).
3 is a result of measuring the elastase inhibition activity of the non-fermented Centella asiatica extract (NF) and the fermented Centella asiatica extract (F/3). The positive control group was treated with URS (ursonic acid, 0.05%).
4 is a result of measuring the lipoxygenase inhibition activity of non-fermented Centella asiatica extract (NF) and fermented Centella asiatica extract (F/3). The positive control group was treated with IDM (Indomethacine, 0.05%).
5 is a result of measuring the elastase inhibitory activity of the fermented Centella asiatica extract according to the fermented strain. A positive control group was treated with URS (ursonic acid, 0.05%), NF is a non-fermented Centella asiatica extract treatment group, L1106 is Lactobacillus fermentum ( Lactobacillus fermentum ) L1106 KCTC 3112; Lb is Lactobacillus brevis ( Lactobacillus brevis ) KCTC 3498; Bs is Bacillus subtilis KACC 91157; And S40 represents the fermented Centella asiatica extract treatment group prepared by inoculating each of the Bacillus sp. S-40 strains.
6 is a result of measuring the elastase inhibitory activity of the fermented Centella asiatica extract according to the fermentation period after inoculation with the Lactobacillus permentum (L1106) strain. The positive control group was treated with URS (ursonic acid, 0.05%), and NF was treated with the non-fermented Centella asiatica extract; F/1 is 1 day; F/2 for 2 days; F/3 is 3 days; F/4 is 4 days; and F/5 represents the fermented Centella asiatica extract treated group prepared by fermenting each for 5 days.
7 is a result of measuring the lipoxygenase inhibitory activity of the fermented Centella asiatica extract according to the fermented strain. Positive control is IDM (Indomethacine, 0.05%) treated, NF is non-fermented Centella asiatica extract treated group, L1106 is Lactobacillus fermentum ( Lactobacillus fermentum ) L1106 KCTC 3112; Lb is Lactobacillus brevis ( Lactobacillus brevis ) KCTC 3498; Bs is Bacillus subtilis KACC 91157; And S40 represents the fermented Centella asiatica extract treatment group prepared by inoculating each of the Bacillus sp. S-40 strains.
8 is a result of measuring the lipoxygenase inhibitory activity of the fermented Centella asiatica extract according to the fermentation period after inoculation of the Lactobacillus permentum (L1106) strain. The positive control group was treated with IDM (Indomethacine, 0.05%), and NF was treated with the non-fermented Centella asiatica extract; F/1 is 1 day; F/2 for 2 days; F/3 is 3 days; F/4 is 4 days; and F/5 represents the fermented Centella asiatica extract treated group prepared by fermenting each for 5 days.
본 발명의 목적을 달성하기 위하여, 본 발명은 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 피부주름 개선용 화장료 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a cosmetic composition for improving skin wrinkles comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
본 발명의 일 구현 예에 따른 피부주름 개선용 화장료 조성물에서, 상기 발효 병풀은 병풀 분말에 유산균을 접종하여 발효한 것일 수 있고, 바람직하게는 병풀(Centella asiatica) 분말에 락토바실러스 퍼멘텀(Lactobacillus fermentum)을 접종하여 1~4일 동안 고상 발효한 것일 수 있으며, 더욱 바람직하게는 2~3일 동안 고상 발효한 것일 수 있으며, 가장 바람직하게는 3일 동안 고상 발효한 것일 수 있으나, 이에 제한되지 않는다.In the cosmetic composition for improving skin wrinkles according to an embodiment of the present invention, the fermented Centella asiatica may be fermented by inoculating lactic acid bacteria in Centella asiatica powder, preferably Centella asiatica, Lactobacillus fermentum in powder. ) may be inoculated and solid-phase fermented for 1 to 4 days, more preferably may be solid-phase fermentation for 2-3 days, and most preferably may be solid-phase fermentation for 3 days, but is not limited thereto .
상기 발효 병풀 추출물은 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합물을 추출용매로 이용하여 추출한 것일 수 있고, 바람직하게는 물을 추출용매로 이용하여 추출한 것일 수 있으나, 이에 제한되지 않는다.The fermented Centella asiatica extract may be extracted using water, a lower alcohol having 1 to 4 carbon atoms, or a mixture thereof as an extraction solvent, and preferably may be extracted using water as an extraction solvent, but is not limited thereto.
본 발명에 따른 발효 병풀 추출물은 비발효 병풀 추출물에 비해 총 페놀의 함량이 높고 DPPH 라디칼 소거 활성이 우수할 뿐만 아니라 피부주름 생성에 주요원인인 엘라스타아제(elastase) 활성을 저해시켜 항산화 및 피부주름 개선에 효과가 있다.The fermented Centella asiatica extract according to the present invention has a higher total phenol content than the non-fermented Centella asiatica extract and has excellent DPPH radical scavenging activity, as well as inhibiting elastase activity, which is a major cause of skin wrinkle formation, thereby providing antioxidant and skin wrinkles. effective for improvement.
본 발명의 상기 피부주름 개선용 화장료 조성물은 스킨, 스킨 소프트너, 스킨 토너, 로션, 밀크로션, 모이스쳐로션, 영양로션, 마사지크림, 영양크림, 아이크림, 모이스쳐크림, 핸드크림, 에센스, 영양에센스, 팩, 클렌징폼, 클렌징워터, 클렌징크림, 바디로션, 바디클렌져, 비누 및 파우더 중에서 선택된 어느 하나의 제형을 가질 수 있으나, 이에 제한되지 않는다. 이들 각 제형으로 이루어진 화장료 조성물은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 당업자에 의해 용이하게 선정될 수 있다.The cosmetic composition for improving skin wrinkles of the present invention is a skin, skin softener, skin toner, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, eye cream, moisture cream, hand cream, essence, nourishing essence , pack, cleansing foam, cleansing water, cleansing cream, body lotion, body cleanser, may have any one formulation selected from soap and powder, but is not limited thereto. The cosmetic composition consisting of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화 아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as a carrier component etc. may be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판-부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydro It may contain a propellant such as carbon, propane-butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene. fatty acid esters of glycol, 1,3-butylglycol oil, glycerol fatty esters, polyethylene glycol or sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanth may be used.
본 발명의 화장료 조성물의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 아세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acetionate, imidazolinium derivative, methyl taurate, sarcosinate as carrier components , fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linoline derivative or ethoxylated glycerol fatty acid ester, etc. may be used.
본 발명의 화장료 조성물은 형광물질, 살진균제, 굴수성 유발물질, 보습제, 방향제, 방향제 담체, 단백질, 용해화제, 당 유도체, 일광차단제, 비타민, 식물 추출물 등을 포함하는 부형제를 추가로 함유할 수 있다.The cosmetic composition of the present invention may further contain excipients including fluorescent substances, fungicides, hydrophobicity-inducing substances, moisturizers, fragrances, fragrance carriers, proteins, solubilizers, sugar derivatives, sunscreens, vitamins, plant extracts, and the like. .
본 발명은 또한, 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 피부주름 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for improving skin wrinkles comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
본 발명의 상기 건강기능식품 조성물은, 비발효 병풀 추출물에 비해 총 페놀의 함량이 높고 DPPH 라디칼 소거 활성 및 피부주름 생성에 주요원인인 엘라스타아제(elastase)의 저해 활성이 증가된 발효 병풀 추출물을 유효성분으로 포함하고 있어, 피부주름 개선에 효과가 있다.The health functional food composition of the present invention contains a fermented Centella asiatica extract with a higher total phenol content than the non-fermented Centella asiatica extract, and the inhibitory activity of elastase, which is a major cause of DPPH radical scavenging activity and skin wrinkle formation. As it is included as an active ingredient, it is effective in improving skin wrinkles.
본 발명의 발효 병풀 추출물을 식품첨가물로 사용하는 경우, 상기 발효 병풀 추출물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 발효 병풀 추출물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양의로 첨가된다. 그러나 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 안전성 면에서 아무런 문제가 없는 범위의 양으로 사용될 수 있다.When the fermented Centella asiatica extract of the present invention is used as a food additive, the fermented Centella asiatica extract may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be used appropriately depending on the purpose of its use (prevention or improvement). In general, in the production of food or beverage, the fermented Centella asiatica extract of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health control, it can be used in an amount within a range that does not cause any problems in terms of safety.
상기 식품의 종류에는 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다. 상기 음료는 탄산음료, 기능성이온음료, 쥬스(예를 들어, 사과, 배,포도, 알로에, 감귤, 복숭아, 당근, 토마토쥬스 등), 식혜 등을 포함한다.There is no particular limitation on the type of the food. Examples of foods to which the health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea There are drinks, alcoholic beverages, vitamin complexes, and the like, and includes all health foods in the ordinary sense. The beverage includes carbonated beverages, functional ionic beverages, juices (eg, apple, pear, grape, aloe, tangerine, peach, carrot, tomato juice, etc.), sikhye, and the like.
본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다. 상기 건강기능식품 조성물 외에 여러가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다.The functional food of the present invention includes ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrin, cyclodextrin, etc.) or sugar alcohols (eg, , xylitol, sorbitol, erythritol, etc.). As the flavoring agent, natural flavoring agents (eg, taumatine, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used. In addition to the health functional food composition, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonated beverages It may further contain a carbonation agent, etc. used for
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 저해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above health functional food composition, various nutrients, vitamins, inhibitors, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, It may further contain a carbonation agent, etc. used in carbonated beverages. The ratio of these added ingredients is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
본 발명은 또한, 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 피부주름 개선용 피부외용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for external use for skin wrinkle improvement comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
본 발명의 피부주름 개선용 피부외용 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 더 포함할 수 있다.The pharmaceutical composition for external application for skin wrinkle improvement of the present invention may further include an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition.
본 발명에 따른 발효 병풀 추출물을 포함하는 피부외용 약학조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부외용 약학조성물을 제공한다. 발효 병풀 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 또는 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.The pharmaceutical composition for external application to the skin comprising the fermented Centella asiatica extract according to the present invention provides a pharmaceutical composition for external application to the skin of a cream, gel, patch, spray, ointment, warning agent, lotion, liniment agent, pasta agent or cataplasma agent. Carriers, excipients or diluents that may be included in the composition comprising the fermented Centella asiatica extract include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is prepared using diluents or excipients, such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
본 발명의 발효 병풀 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물 또는 이의 분획물은 1일 0.0001 내지 100㎎/㎏으로, 바람직하게는 0.001 내지 10㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the fermented Centella asiatica extract of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the drug form, the route of administration, and the duration, but may be appropriately selected by those skilled in the art. However, for a desirable effect, the extract or its fraction of the present invention is preferably administered at 0.0001 to 100 mg/kg per day, preferably at 0.001 to 10 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
본 발명은 또한, 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also provides a health functional food composition for the prevention or improvement of inflammatory diseases comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
본 발명의 상기 건강기능식품 조성물은, 비발효 병풀 추출물에 비해 총 페놀의 함량이 높고, DPPH 라디칼 소거 활성 및 염증유발 인자인 리폭시게나아제(lipoxygenase) 억제 활성이 증가된 발효 병풀 추출물을 유효성분으로 포함하고 있어, 염증성 질환에 효과가 있다.The health functional food composition of the present invention contains, as an active ingredient, a fermented Centella asiatica extract having a higher total phenol content than the non-fermented Centella asiatica extract, and having an increased DPPH radical scavenging activity and lipoxygenase inhibitory activity, which is an inflammation-inducing factor. It is effective for inflammatory diseases.
상기 염증성 질환의 예방 또는 개선용 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽, 발포정 및 음료 중에서 선택된 어느 하나의 제형으로 제조될 수 있으나, 이에 제한되지 않는다. 상기 건강기능식품 조성물은 항염증 활성을 증가시키기 위해 섭취할 수 있는 것이면 특별히 제한되지 않는다.The health functional food composition for preventing or improving the inflammatory disease may be prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, effervescent tablet and beverage, but is not limited thereto. The health functional food composition is not particularly limited as long as it can be ingested to increase anti-inflammatory activity.
본 발명의 발효 병풀 추출물을 식품첨가물로 사용하는 경우 식품의 종류, 식품 제조시 통상적으로 첨가되는 성분은 상기 전술한 바와 같다.When the fermented Centella asiatica extract of the present invention is used as a food additive, the type of food and the ingredients commonly added during food production are as described above.
본 발명은 또한, 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising a fermented Centella asiatica extract with enhanced antioxidant activity as an active ingredient.
본 발명의 염증성 질환의 예방 또는 치료용 약학조성물에서, 상기 염증성 질환은 알레르기, 피부염, 아토피, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증, 및 급성 및 만성 염증 질환으로 이루어지는 군으로부터 선택되는 어느 하나일 수 있으나, 이에 제한되지 않는다.In the pharmaceutical composition for preventing or treating an inflammatory disease of the present invention, the inflammatory disease is allergy, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing Spondylitis, rheumatoid fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, parotiditis, tendinitis, tendinitis, tendonitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute And it may be any one selected from the group consisting of chronic inflammatory diseases, but is not limited thereto.
본 발명의 상기 약학 조성물은, 염증유발 인자인 리폭시게나아제(lipoxygenase)의 저해 활성이 증가된 발효 병풀 추출물을 유효성분으로 포함하고 있어, 염증성 질환에 효과가 있다. 또한, 본 발명에 따른 상기 발효 병풀 추출물은 항산화 효과가 우수하다.The pharmaceutical composition of the present invention contains, as an active ingredient, a fermented Centella asiatica extract having increased inhibitory activity of lipoxygenase, an inflammation-inducing factor, and is effective in inflammatory diseases. In addition, the fermented Centella asiatica extract according to the present invention has excellent antioxidant effect.
본 발명의 약학 조성물의 약학적 투여 형태는 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 조합으로 사용될 수 있으며, 본 발명의 약학 조성물의 바람직한 투여량은 상기 전술한 바와 같다.The pharmaceutical dosage form of the pharmaceutical composition of the present invention may be used alone or in combination with other pharmaceutically active compounds as well as in an appropriate combination, and the preferred dosage of the pharmaceutical composition of the present invention is as described above.
이하, 본 발명을 실시예에 의해 상세히 설명한다 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of Examples. However, the following Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples.
재료 및 방법Materials and Methods
1. 실험 재료 및 발효 조건1. Experimental Materials and Fermentation Conditions
본 발명에 사용된 병풀은 (주)오케이바이오랩으로부터 제공받아 분말화시킨 후 냉장보관하였다. 병풀 발효에는 유산균의 일종인 락토바실러스 퍼멘텀(Lactobacillus fermentum) L1106 KCTC 3112 균주를 선택하여 사용하였고, 균주를 전배양하고 병풀 분말의 중량 대비 50%(v/w)만큼 접종한 후 37℃에서 3일간 고상 발효하고 60℃에서 8시간 동안 열풍 건조시켜 분말화하였다.Centella asiatica used in the present invention was provided from OK Biolab Co., Ltd., powdered, and then stored refrigerated. For the fermentation of Centella asiatica, Lactobacillus fermentum L1106 KCTC 3112 strain, a type of lactic acid bacteria, was selected and used. It was powdered by solid-state fermentation for one day and hot air drying at 60° C. for 8 hours.
2. 발효 병풀 추출물의 제조2. Preparation of fermented Centella asiatica extract
발효 병풀 분말 및 병풀 분말 100g에 10배의 정제수를 각각 첨가한 후 37℃ 항온수조에서 3시간씩 교반하면서 3회 반복 추출하여 물 추출물을 제조하였으며, Adventec 110 mm No2 여과지(Toyo 2A; Toyo Roshi, Tokyo, Japan)로 여과하여 실험에 사용하였다. 상기 비발효 병풀 추출물(NF)과 발효 병풀 추출물(F/3)을 실험에 사용하였다. After adding 10 times purified water to 100 g of fermented Centella asiatica powder and 100 g of Centella asiatica powder, respectively, extraction was repeated three times while stirring for 3 hours in a constant temperature water bath at 37°C to prepare a water extract, and Adventec 110 mm No2 filter paper (Toyo 2A; Toyo Roshi, Tokyo, Japan) was filtered and used for the experiment. The non-fermented Centella asiatica extract (NF) and the fermented Centella asiatica extract (F/3) were used in the experiment.
3. 총 페놀 함량 측정3. Determination of total phenol content
총 페놀 함량은 폴린-데니스(Folin-Denis) 방법을 이용하여 측정하였다. 발효 병풀 추출물과 비발효 병풀 추출물에 페놀용액(Folin-ciocalteu's phenol reagent)을 처리하면 페놀성 물질이 인몰리브덴산(phosphomolybdic acid)과 반응하여 청색으로 변하게 되며, 이를 760nm에서 흡광도를 측정하여 측정하였다. 이때 표준 검량 곡선은 탄닌산(tannic acid)을 일정 농도(0~500μg/㎖)로 하여 상기와 동일한 방법으로 측정하여 획득하였으며, 시료의 흡광도를 표준 검량 곡선에 대입하여 총 페놀 함량을 mg/100g로 나타내었다.Total phenol content was determined using the Folin-Denis method. When the fermented Centella asiatica extract and the non-fermented Centella asiatica extract were treated with a phenol solution (Folin-ciocalteu's phenol reagent), the phenolic substance reacted with phosphomolybdic acid to turn blue, and the absorbance was measured at 760 nm. At this time, the standard calibration curve was obtained by measuring tannic acid at a certain concentration (0 to 500 μg/ml) in the same manner as above, and substituting the absorbance of the sample into the standard calibration curve to set the total phenol content to mg/100 g. indicated.
4. DPPH 라디칼 소거 활성 측정4. Measurement of DPPH radical scavenging activity
에탄올 100㎖에 DPPH(α,α'-diphenyl-β-picrylhydrazyl) 16㎎을 녹이고 증류수 100㎖을 혼합한 후 Whatman 필터지 NO.2에 여과시켜 DPPH 반응 용액을 제조하였다. 10%(w/v)의 비발효 병풀 추출물 또는 발효 병풀 추출물 1㎖를 취한 후 DPPH 반응 용액 5㎖을 넣어 혼합하고 암소에서 30분간 반응시킨 다음 분광광도계를 이용하여 528nm에서 흡광도를 측정하였다. 이때 활성 비교를 위하여 기존에 항산화제로 많이 사용되고 있는 합성 항산화제 BHT(butylated hydroxytoluene)를 0.05% 농도로 사용하여 시료와 동일한 방법으로 흡광도를 측정하였다. DPPH를 이용한 항산화 활성은 시료 첨가구와 무첨가구의 흡광도차를 백분율(%)로 표시하였다. DPPH 라디칼 소거능 활성(radical scavenging activity)을 구하는 식은 하기와 같다.16 mg of DPPH (α,α'-diphenyl-β-picrylhydrazyl) was dissolved in 100 ml of ethanol, mixed with 100 ml of distilled water, and filtered through Whatman filter paper NO.2 to prepare a DPPH reaction solution. After taking 1 ml of 10% (w/v) unfermented Centella asiatica extract or fermented Centella asiatica extract, 5 ml of a DPPH reaction solution was added, mixed, and reacted in a dark place for 30 minutes, and then absorbance was measured at 528 nm using a spectrophotometer. At this time, for comparison of activity, absorbance was measured in the same manner as in the sample using a synthetic antioxidant BHT (butylated hydroxytoluene), which has been widely used as an antioxidant, at a concentration of 0.05%. Antioxidant activity using DPPH was expressed as a percentage (%) of the absorbance difference between the sample-added group and the non-additive group. The formula for calculating the DPPH radical scavenging activity is as follows.
DPPH 라디칼 소거능 활성(%)=[1-(시료 흡광도528nm)/대조구 흡광도528nm]×100DPPH radical scavenging activity (%) = [1- (sample absorbance 528 nm ) / control absorbance 528 nm ] × 100
5. 엘라스타아제(elastase) 억제 활성5. Elastase inhibitory activity
1%(w/v)의 비발효 병풀 추출물 또는 발효 병풀 추출물 15㎕에 100mM의 Tris-HCl 버퍼(pH 8.0)에 녹인 돼지의 췌장 엘라스타아제(porcine pancreas elastase, 0.2 unit/㎖) 5㎕와 N-숙시닐-(L-Ala)3-p-나이트로아닐라이드(N-succcinyl-(L-Ala)3-p-nitroa-nilide, 0.5 mg/mL)를 녹인 기질액 20㎕를 첨가하여 37℃에서 10분간 반응시켰다. 그 후 얼음에서 5분간 냉각시킨 후 410nm에서 흡광도를 측정하였다. 양성대조군은 URS(ursonic acid, Sigma) 0.05%를 처리하였다.5 μl of porcine pancreas elastase (0.2 unit/ml) dissolved in 100 mM Tris-HCl buffer (pH 8.0) in 15 μl of 1% (w/v) unfermented Centella asiatica extract or fermented Centella asiatica extract 20 μl of a substrate solution in which N-succinyl-(L-Ala)3-p-nitroanilide (N-succinyl-(L-Ala)3-p-nitroa-nilide, 0.5 mg/mL) was dissolved was added. The reaction was carried out at 37°C for 10 minutes. Then, after cooling on ice for 5 minutes, absorbance was measured at 410 nm. The positive control group was treated with URS (ursonic acid, Sigma) 0.05%.
6. 리폭시게나아제(lipoxygenase) 억제 활성6. Lipoxygenase inhibitory activity
1%(w/v)의 비발효 병풀 추출물 또는 발효 병풀 추출물 100㎕와 200mM 보레이트 완충액(borate buffer, pH 9.0) 1㎖을 넣은 후 기질인 리놀렌산(linoleic acid, 0.6 mM/㎖ in ethanol) 2㎖을 넣고 혼합한 후 234nm에서 보정값을 측정한 다음, 리폭시게나아제 10,000 unit/㎖ 100㎕를 넣고 상온에서 10분간 반응시킨 후 234nm에서 흡광도를 측정하였으며, 양성대조군은 인도메타신(indomethacin, Sigma)을 0.05%(w/v)로 에탄올에 녹여서 사용하였다.After adding 100 μl of 1% (w/v) non-fermented Centella asiatica extract or fermented Centella asiatica extract and 1 mL of 200 mM borate buffer (pH 9.0), 2 mL of substrate linoleic acid (0.6 mM/mL in ethanol) After mixing, the correction value was measured at 234 nm, and 100 μl of lipoxygenase 10,000 unit/ml was added and reacted at room temperature for 10 minutes, and absorbance was measured at 234 nm. was used by dissolving in ethanol at 0.05% (w/v).
리폭시게나아제 억제활성(%)={1-(b'-b)/(a'-a)}×100Lipoxygenase inhibitory activity (%) = {1-(b'-b)/(a'-a)}×100
b: 효소 무첨가 시료’b: Enzyme-free sample’
b : 효소 첨가 시료군b: enzyme-added sample group
a: 효소 무첨가 blank 군a: enzyme-free blank group
a': 효소 첨가 blank 군a': enzyme-added blank group
7. 통계처리7. Statistical processing
상기 실험으로부터 얻어진 결과는 one-way ANOVA 검정에 의한 평균±표준편차로 표시하였고, 각 실험 군 간의 유의성 검증은 Duncan's multiple range test로 나타내었다.The results obtained from the above experiments were expressed as mean ± standard deviation by one-way ANOVA test, and the significance test between each experimental group was indicated by Duncan's multiple range test.
실시예Example 1. 발효 병풀 추출물의 총 페놀 함량 분석 1. Analysis of total phenol content of fermented Centella asiatica extract
비발효 병풀 추출물과 발효 병풀 추출물의 총 페놀 함량을 측정한 결과, 도 1에 개시한 바와 같이 총 페놀 함량은 NF군에서 19.21mg/100g인 반면, F/3군에서 28.37mg/100g인 것으로, 비발효 병풀 추출물에 비해 발효 병풀 추출물에서 총 페놀 함량이 증가하였고 NF군 및 F/3군 간에 통계적으로 유의한 차이가 있는 것을 확인하였다. As a result of measuring the total phenol content of the non-fermented Centella asiatica extract and the fermented Centella asiatica extract, as shown in FIG. 1 , the total phenol content was 19.21 mg/100 g in the NF group, whereas it was 28.37 mg/100 g in the F/3 group, It was confirmed that the total phenol content was increased in the fermented Centella asiatica extract compared to the non-fermented Centella asiatica extract, and there was a statistically significant difference between the NF group and the F/3 group.
실시예Example 2. 발효 병풀 추출물의 2. Fermented Centella asiatica extract DPPHDPPH 라디칼radical 소거 활성 분석 Scavenging Activity Assay
비발효 병풀 추출물 및 발효 병풀 추출물의 DPPH 라디칼 소거 활성을 측정하였고, 양성대조군에는 시중에서 판매하고 있는 합성 항산화제인 BHT 0.05%를 처리하였다. 그 결과, DPPH 라디칼 소거 활성이 비발효 병풀 추출물 처리군(NF)에서 63.12%인 반면, 발효 병풀 추출물 처리군(F/3)에서 73.01%로 DPPH 라디칼 소거 활성이 증가하였고, NF군 및 F/3군 간에 통계적으로 유의한 차이가 있는 것을 확인하였다(도 2).The DPPH radical scavenging activity of the non-fermented Centella asiatica extract and the fermented Centella asiatica extract was measured, and the positive control group was treated with BHT 0.05%, a commercially available synthetic antioxidant. As a result, while the DPPH radical scavenging activity was 63.12% in the non-fermented Centella asiatica extract treatment group (NF), the DPPH radical scavenging activity increased to 73.01% in the fermented Centella asiatica extract treated group (F/3), and the NF group and F/ It was confirmed that there was a statistically significant difference between the three groups (FIG. 2).
실시예 3. 발효 병풀 추출물의 엘라스타아제 저해 활성 분석Example 3. Elastase inhibitory activity analysis of fermented Centella asiatica extract
엘라스틴(elastin)은 콜라겐과 같이 피부 탄력에 관여하고 있는 주름 생성에 중요한 섬유 조직이다. 엘라스틴 섬유의 결핍과 응집, 엘라스타아제의 활성도의 현격한 증가는 피부주름 생성 요인 중의 하나이다. 엘라스틴을 분해할 수 있는 유일한 효소인 엘라스타아제를 저해하는 것은 피부주름을 근본적으로 줄여 줄 수 있다고 알려져 있다. 비발효 병풀 추출물 및 발효 병풀 추출물의 엘라스타아제 저해 활성을 측정한 결과, 엘라스타아제 저해 활성이 NF군에서 3.95%인 반면, F/3군에서 22.69%인 것으로, 비발효 병풀 추출물에 비해 발효 병풀 추출물에서 엘라스타아제 저해 활성이 약 5.7배 증가한 것을 확인하였다(도 3). Elastin, like collagen, is an important fibrous tissue that is involved in skin elasticity and wrinkle formation. Deficiency and aggregation of elastin fibers and a marked increase in the activity of elastase are one of the factors that cause skin wrinkles. It is known that inhibiting elastase, the only enzyme that can break down elastin, can radically reduce skin wrinkles. As a result of measuring the elastase inhibitory activity of the non-fermented Centella asiatica extract and the fermented Centella asiatica extract, the elastase inhibitory activity was 3.95% in the NF group and 22.69% in the F/3 group, compared to the non-fermented Centella asiatica extract. It was confirmed that the elastase inhibitory activity in Centella asiatica extract increased about 5.7 times (FIG. 3).
실시예Example 4. 발효 병풀 추출물의 리폭시게나아제 저해 활성 분석 4. Lipoxygenase inhibitory activity analysis of fermented Centella asiatica extract
리폭시게나아제(lipoxygenase)는 정상적인 세포에서는 발현이 미비하지만, 염증이 유발되면 류코트리엔(leukotrienes) 물질의 증가로 인해 활성을 나타낸다. 비발효 병풀 추출물 및 발효 병풀 추출물의 리폭시게나아제 저해 활성을 측정한 결과, 리폭시게나아제 저해 활성이 NF군에서 20.14%인 반면, F/3군에서 43.8%인 것으로, 비발효 병풀 추출물에 비해 발효 병풀 추출물에서 리폭시게나아제 저해 활성이 약 2.2배 증가하였고 NF군 및 F/3군 간에 통계적으로 유의한 차이가 있는 것을 확인하였다(도 4). Lipoxygenase (lipoxygenase) is poorly expressed in normal cells, but exhibits activity due to an increase in leukotrienes when inflammation is induced. As a result of measuring the lipoxygenase inhibitory activity of the non-fermented Centella asiatica extract and the fermented Centella asiatica extract, the lipoxygenase inhibitory activity was 20.14% in the NF group and 43.8% in the F/3 group, compared to the non-fermented Centella asiatica extract. The lipoxygenase inhibitory activity in Centella asiatica extract was increased by about 2.2-fold, and it was confirmed that there was a statistically significant difference between the NF group and the F/3 group ( FIG. 4 ).
실시예 5. 발효 균주 및 기간에 따른 엘라스타아제 저해 활성 분석Example 5. Elastase inhibitory activity analysis according to fermentation strain and period
상기 동일한 방법으로 발효 균주(Lactobacillus fermentum L1106 KCTC 3112, Lactobacillus brevis KCTC 3498, Bacillus subtilis KACC 91157 및 Bacillus sp. S-40)별로 고상 발효 1일 기준으로 발효 병풀 추출물을 각각 제조하여 엘라스타아제 저해 활성을 측정하였다. 그 결과, NF 처리군과 비교하여 락토바실러스 브레비스(Lactobacillus brevis, Lb), 바실러스 서틸리스(Bacillus subtilis, Bs) 및 바실러스 속(Bacillus sp., S40) 균주를 각각 접종하여 제조한 발효 병풀 추출물 처리군의 경우에 오히려 엘라스타아제 저해 활성이 감소되는 반면, 락토바실러스 퍼멘텀(Lactobacillus fermentum, L1106) 균주를 이용하여 제조한 발효 병출 추출물 처리군에서는 NF 처리군에 비해 엘라스타아제 저해 활성이 현저하게 증가한 것을 확인하였다(도 5).In the same manner, fermentation strains ( Lactobacillus fermentum L1106 KCTC 3112, Lactobacillus brevis KCTC 3498, Bacillus subtilis KACC 91157) and Bacillus sp. S-40), each fermented Centella asiatica extract was prepared on the basis of 1 day of solid fermentation, and elastase inhibitory activity was measured. As a result, compared to the NF treatment group, Lactobacillus brevis ( Lactobacillus brevis , Lb), Bacillus subtilis ( Bacillus subtilis , Bs) and Bacillus sp. (Bacillus sp., S40) In the case of the fermented Centella asiatica extract treated group prepared by inoculating each strain, the elastase inhibitory activity is rather reduced, whereas the Lactobacillus fermentum (L1106) strain It was confirmed that the elastase inhibitory activity was significantly increased in the fermented bottlenose extract treated group compared to the NF-treated group (FIG. 5).
또한, 락토바실러스 퍼멘텀(L1106) 균주를 접종하여 발효 기간(1, 2, 3, 4 및 5일)별로 발효 병풀 추출물을 제조하여 엘라스타아제 저해 활성을 측정한 결과, 발효 기간 중 3일째에서 엘라스타아제 저해 활성이 가장 우수한 것을 확인하였다(도 6).In addition, as a result of measuring the elastase inhibitory activity by inoculating Lactobacillus permentum (L1106) strain to prepare fermented Centella asiatica extract for each fermentation period (1, 2, 3, 4 and 5 days), on the third day of the fermentation period It was confirmed that the elastase inhibitory activity was the best (FIG. 6).
실시예 6. 발효 균주 및 기간에 따른 리폭시게나아제 저해 활성 분석Example 6. Lipoxygenase inhibitory activity analysis according to fermentation strain and period
상기 동일한 방법으로 발효 균주(Lactobacillus fermentum L1106 KCTC 3112, Lactobacillus brevis KCTC 3498, Bacillus subtilis KACC 91157 및 Bacillus sp. S-40)별로 고상 발효 1일 기준으로 발효 병풀 추출물을 각각 제조하여 리폭시게나아제 저해 활성을 측정하였다. 그 결과, NF 처리군과 비교하여 락토바실러스 브레비스(Lactobacillus brevis, Lb), 바실러스 서틸리스(Bacillus subtilis, Bs) 및 바실러스 속(Bacillus sp., S40) 균주를 각각 접종하여 제조한 발효 병풀 추출물 처리군의 경우에 오히려 리폭시게나아제 저해 활성이 현저하게 감소되는 반면, 락토바실러스 퍼멘텀(Lactobacillus fermentum, L1106) 균주를 이용하여 제조한 발효 병출 추출물 처리군에서는 NF 처리군에 비해 리폭시게나아제 저해 활성이 통계적으로 유의하게 증가한 것을 확인하였다(도 7).In the same manner, fermentation strains ( Lactobacillus fermentum L1106 KCTC 3112, Lactobacillus brevis KCTC 3498, Bacillus subtilis KACC 91157) and Bacillus sp. S-40), each fermented Centella asiatica extract was prepared on the basis of 1 day of solid-phase fermentation, and lipoxygenase inhibitory activity was measured. As a result, compared to the NF treatment group, Lactobacillus brevis ( Lactobacillus brevis , Lb), Bacillus subtilis ( Bacillus subtilis , Bs) and Bacillus sp., whereas in the case of the fermented Centella asiatica extract treated group prepared by inoculating each strain, the lipoxygenase inhibitory activity was significantly reduced, Lactobacillus fermentum ( L1106) It was confirmed that the lipoxygenase inhibitory activity was statistically significantly increased in the fermented bottlenose extract treated group prepared using the strain compared to the NF-treated group (FIG. 7).
또한, 락토바실러스 퍼멘텀(L1106) 균주를 접종하여 발효 기간(1, 2, 3, 4 및 5일)별로 발효 병풀 추출물을 제조하여 리폭시게나아제 저해 활성을 측정한 결과, 발효 기간 중 3일째에서 리폭시게나아제 저해 활성이 가장 우수한 것을 확인하였다(도 8).In addition, the Lactobacillus permentum (L1106) strain was inoculated to prepare a fermented Centella asiatica extract for each fermentation period (1, 2, 3, 4 and 5 days) and the lipoxygenase inhibitory activity was measured. It was confirmed that the lipoxygenase inhibitory activity was the best (FIG. 8).
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190164117A KR102314654B1 (en) | 2019-12-10 | 2019-12-10 | Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190164117A KR102314654B1 (en) | 2019-12-10 | 2019-12-10 | Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210073700A KR20210073700A (en) | 2021-06-21 |
| KR102314654B1 true KR102314654B1 (en) | 2021-10-21 |
Family
ID=76600204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190164117A KR102314654B1 (en) | 2019-12-10 | 2019-12-10 | Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102314654B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230013234A (en) * | 2021-07-14 | 2023-01-26 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating respiratory disease comprising fermented Centella asiatica extract as effective component |
| KR102579401B1 (en) * | 2023-03-27 | 2023-09-18 | 주식회사 클린뷰티코리아 | A multi-functional cosmetic composition containing Jeju Dongchimi-derived lactic acid bacteria and Jeju camellia flower extract effective for anti-aging, wrinkle improvement, and cell regeneration as active ingredients |
| KR102655580B1 (en) * | 2023-11-27 | 2024-04-09 | 주식회사 올바른 | Cosmetic composition with skin soothing effect and method for manufacturing the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101739422B1 (en) | 2016-03-14 | 2017-05-26 | (주)진셀팜 | Composition for improving skin conditions and preventing or treating proliferative skin diseases containing centella asiatica extracts originated from plant factory |
| KR101971837B1 (en) | 2018-09-19 | 2019-04-23 | 동국제약 주식회사 | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130085012A (en) * | 2012-01-18 | 2013-07-26 | 주식회사 엘지생활건강 | Cosmetic composition comprising fermented material and manufacturing method thereof |
| KR101631453B1 (en) * | 2013-09-30 | 2016-06-27 | (주) 비에스티 | Composition for Protecting Ultraviolet Rays from Damaging Skin Originated from Extracts of Plants or Fermentation Thereof and Method for Producing the Same |
-
2019
- 2019-12-10 KR KR1020190164117A patent/KR102314654B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101739422B1 (en) | 2016-03-14 | 2017-05-26 | (주)진셀팜 | Composition for improving skin conditions and preventing or treating proliferative skin diseases containing centella asiatica extracts originated from plant factory |
| KR101971837B1 (en) | 2018-09-19 | 2019-04-23 | 동국제약 주식회사 | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210073700A (en) | 2021-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102314654B1 (en) | Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component | |
| KR20210114893A (en) | Cosmetic and OTC drug composition comprising peach fermented extract as an active ingredient | |
| KR101936294B1 (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
| KR101876669B1 (en) | Novel Pichia kudriavzevii and Use thereof | |
| KR102350102B1 (en) | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component | |
| KR101876668B1 (en) | Novel Saccharomycopsis fibuligera and Use thereof | |
| KR101889647B1 (en) | Novel Lactobacillus Harbinensis and Use thereof | |
| KR20190061544A (en) | Cosmetic Composition for Anti-oxidation and Whitening comprising fermented silkworm extract as effective component | |
| KR101863895B1 (en) | Composition for skin whitening comprising Stachys sieboldii extract fermented using Hericium erinaceum mycelium as effective component | |
| KR102159607B1 (en) | Composition for skin whitening or anti-inflammatory comprising extract of fermented Angelica gigas with improved antioxidant activity as effective component | |
| KR102599579B1 (en) | Nanorization-treated fermented Hibiscus manihot with enhanced collagen, amino acid, polyphenol or flavonoid content and manufacturing method thereof | |
| KR102314639B1 (en) | Composition for anti-inflammation comprising extract of fermented bamboo shoot bark with improved antioxidant activity as effective component | |
| KR102370528B1 (en) | Compositions containing Beta vulgaris fermentation extract | |
| KR102302072B1 (en) | Method for producing fermented Beta vulgaris extract with improved antioxidant activity and fermented Beta vulgaris extract produced by the same method | |
| KR102331119B1 (en) | Composition for preventing skin anti-aging comprising fermented black rice extract and fermented peanut sprout extract | |
| KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
| KR102235186B1 (en) | Composition for anti-inflammation comprising coconut oil with fermentation and ripening as effective component and manufacturing method thereof | |
| KR20210155987A (en) | Composition Comprising Complex Extract of seaweeds Fermented by Lactobacillus Brevis with Anti-Wrinkling and Elasticity, Antioxidant, and Skin Hydration Property as Active Ingredient | |
| JP4902967B2 (en) | Melanin production inhibitor | |
| KR102239470B1 (en) | Composition for skin whitening comprising extract of fermented black rice with improved antioxidant activity as effective component | |
| JP2005089385A (en) | Lipoxygenase inhibitor | |
| KR102670653B1 (en) | Composition for improving hair loss containing fermented product of lactic acid bacteria of Helianthus tuberosus extract | |
| KR102532713B1 (en) | Novel Saccharomyces cerevisiae strain and use thereof | |
| WO2024117771A1 (en) | Composition including colored rice extract as active ingredient for prevention, reduction, or treatment of skin wrinkles | |
| KR102539089B1 (en) | Composition for skin whitening and anti-oxidant comprising fermented product of Angelica dahurica extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |